Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
Sign Up to like & getrecommendations! Published in 2018 at "Oncogene"
DOI: 10.1038/s41388-018-0454-2
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is a major advance in treating NSCLC with EGFR-activating mutations. However, acquired resistance, due partially to secondary mutations limits their use. Here we report that NSCLC… read more here.
Keywords: egfr mutations; common mechanism; acquired resistance; resistance ... See more keywords